| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | IGFBP2; BP2; IBP2; Insulin-like growth factor-binding protein 2; IBP-2; IGF-binding protein 2; IGFBP-2 |
| Entrez GeneID | 3485 |
| WB Predicted band size | Calculated MW: 35 kDa; Observed MW: 35 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Recombinant protein of human IGFBP2 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于IGFBP2抗体的3篇参考文献示例：
1. **"IGFBP2 is a biomarker for predicting poor prognosis in glioblastoma"**
- **作者**: Wang et al.
- **摘要**: 该研究通过免疫组化(IHC)和Western blot使用IGFBP2抗体，发现IGFBP2在胶质母细胞瘤中高表达，并与患者生存期缩短相关，提示其作为预后标志物的潜力。
2. **"IGFBP2 promotes adipose tissue inflammation and insulin resistance in obesity"**
- **作者**: Smith & Jones
- **摘要**: 研究者利用IGFBP2特异性抗体阻断小鼠模型中的IGFBP2功能，发现其减轻脂肪组织炎症并改善胰岛素敏感性，揭示了IGFBP2在肥胖相关代谢紊乱中的作用机制。
3. **"Circulating IGFBP2 as a diagnostic marker for early-stage ovarian cancer"**
- **作者**: Zhang et al.
- **摘要**: 通过ELISA和免疫沉淀技术结合IGFBP2抗体，研究发现血液中IGFBP2水平在卵巢癌早期显著升高，提出其作为无创诊断工具的潜在价值。
4. **"IGFBP2 modulates amyloid-beta clearance in Alzheimer’s disease models"**
- **作者**: Lee et al.
- **摘要**: 该研究利用IGFBP2抗体在小鼠脑组织中进行免疫荧光染色，证实IGFBP2通过影响淀粉样蛋白β的清除加剧阿尔茨海默病病理进程。
(注：以上为示例文献，实际引用需根据具体研究检索确认。)
The insulin-like growth factor binding protein 2 (IGFBP2) is a member of the IGFBP family, which comprises six proteins (IGFBP1-6) that regulate the bioavailability and activity of insulin-like growth factors (IGFs). IGFBP2 primarily binds to IGF-1 and IGF-2. modulating their interactions with IGF receptors to influence cell proliferation, differentiation, and survival. Beyond IGF-dependent functions, IGFBP2 exhibits IGF-independent roles, including interactions with integrins, extracellular matrix components, and intracellular signaling pathways, impacting processes like angiogenesis, metabolism, and tumor progression.
IGFBP2 antibodies are essential tools for detecting and quantifying IGFBP2 in research and clinical settings. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and enzyme-linked immunosorbent assays (ELISA) to study IGFBP2 expression patterns in tissues, serum, or cell cultures. Elevated IGFBP2 levels are associated with various cancers (e.g., glioblastoma, breast, and ovarian cancers), where it often correlates with tumor aggressiveness, metastasis, and poor prognosis. Additionally, IGFBP2 dysregulation is implicated in metabolic disorders, obesity, and neurodegenerative diseases.
Research using IGFBP2 antibodies has highlighted its dual role as both a biomarker and a potential therapeutic target. Neutralizing antibodies are being explored to inhibit IGFBP2’s oncogenic activities. However, its context-dependent functions—acting as either a tumor suppressor or promoter—underscore the need for nuanced studies. Understanding IGFBP2’s molecular mechanisms through antibody-based assays remains critical for advancing diagnostics and targeted therapies.
×
